Source comparison
TB-500 vs Minoxidil vs Finasteride: Pathway Comparison
Primary Action Actin sequestration in follicle stem cells; Wnt/β-catenin pathway activation ATP-sensitive potassium channel opening; increased cutaneous blood flow 5-alpha reductase Type II inhibition; reduced DHT conversion from testosterone TB-500 is the onl
This comparison does not assign a generated winner or score.
- Primary Action
- Actin sequestration in follicle stem cells; Wnt/β-catenin pathway activation
- ATP-sensitive potassium channel opening; increased cutaneous blood flow
- 5-alpha reductase Type II inhibition; reduced DHT conversion from testosterone
- TB-500 is the only compound targeting stem cell quiescence directly. But lacks human trial validation
- Angiogenesis Effect
- Direct VEGF upregulation in dermal papilla cells (2.8× increase in vitro)
- Indirect vasodilation through smooth muscle relaxation
- No direct vascular effect
- TB-500's VEGF mechanism is more targeted than minoxidil's generalized vasodilation
- Clinical Evidence Base
- Murine models only; no Phase III human data
- FDA-approved 1988; 60% response rate at 12 months (5% solution)
- FDA-approved 1997; 80–90% halt progression; 65% regrowth in vertex
- Finasteride has strongest evidence; TB-500 remains experimental
- Systemic Absorption
- Minimal with topical use; moderate with subcutaneous injection
- Low systemic exposure; primarily topical
- High systemic exposure; affects serum DHT by 70%
- TB-500 systemic effects poorly characterized for scalp application
- Documented Side Effects
- Unknown in humans for hair loss; wound studies report minimal adverse events
- Scalp irritation (4–7%); hypertrichosis (unwanted hair growth)
- Sexual dysfunction (2–4%); potential mood effects
- TB-500's safety profile for chronic scalp use is undefined